DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Mahon FX, Rea D, Guilhot J. et al.
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre stop imatinib (STIM) trial.
Lancet Oncol 2010;
11: 1029-1035
We do not assume any responsibility for the contents of the web pages of other providers.